Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
The Nasal decongestion is a monotherapy used for common cold along with several other breathing illnesses. Pharmaceutical companies are creating high revenues by packing these over-the-counter drugs. A growing body of studies have announced the encouraging result related to the safety and efficacy of nasal decongestant. These key findings have turned on the expansion of prospects in the nasal decongestants market. Both randomized controlled trials and cluster randomized controlled trials have been part of the nasal decongestant trials.
The Asia Pacific nasal decongestant market is observing lucrative growth during forecast period of 2021 to 2027. The nasal decongestant has shown remarkable efficacy in relieving symptoms of the nasal congestion from many years. The dynamics factors such as rising preference towards nasal sprays as a result of easy administration is propelling growth of Asia Pacific nasal decongestant market. The rising adoption of self-administration practises is also boosting growth of Asia Pacific nasal decongestant market. However, complications associated with overuse of medicines is hampering growth of Asia Pacific nasal decongestant market.
The exclusive COVID-19 impact analysis report by Axiom MRC provides a 3600 analysis of micro and macro-economic factors on the nasal decongestant market. In addition, complete analysis of changes on nasal decongestant expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on Asia Pacific economies, international trade, business investments, GDP and marketing strategies of key players present in the market. The healthcare and pharmaceutical companies are going through high pressure for drug innovation to treat coronavirus in patients. The invention of vaccines by key players has lowered the pressure on the pharmaceutical companies to launch drugs for the novel infection. However, key players in nasal decongestant market are rising their R&D efforts. Due to these the nasal decongestant market have experienced positive impact during COVID-19 pandemics.
The Asia Pacific nasal decongestant market is segmented by product type, application and country.
Based on product type, the Asia Pacific nasal decongestant market is segmented into nasal strips, tablets, sprays and capsules. In which capsules is also contributing to the growth of Asia Pacific nasal decongestant market. The nasal decongestant capsules works by thinning and loosening mucus in the airways, clearing congestion and making breathing easier. The capsules are not taken by mouth. Carefully the top off capsules are snipped and the content of capsule is poured onto the tissue or handkerchief and inhaled the vapour freely.
Based on application, the Asia Pacific nasal decongestant market is bifurcated into asthma, cold and nasal allergies. In which asthma is also contributing to the growth of Asia Pacific nasal decongestant market. Asthma is a medical condition in which airways gets narrow and swell and may produce extra mucus. This may make difficulty in breathing along with whistling sound at the time of breath out and shortness of breath. There is several types of asthmas such as adult-onset asthma, allergic asthma, asthma-COPD overlap, exercise induced bronchoconstriction, non-allergic asthma and occupational asthma.
The Asia Pacific nasal decongestant market is studied for key countries such as China, India, Japan, Australia and South Korea. In which China followed by India and Japan are anticipated to dominate the market in 2020. The rising research and development activities in pharmaceutical industries is propelling growth of Asia Pacific nasal decongestant market. The rising population is also refuelling growth of Asia Pacific nasal decongestant market. The growing product launch and key players collaboration is also driving growth of Asia Pacific nasal decongestant market.
The major key players in nasal decongestant market are 3M, Abbott Laboratories, Adapt Pharma Inc., Aegis Therapeutics Llc, Allergan Plc, Aptargroup Inc., Astrazeneca Plc, Bayer, Becton, Dickinson And Company, Cipla, Glaxosmithkline Plc, Innovus Pharmaceuticals Inc., Johnson & Johnson Services Inc., Meda Pharmaceuticals Inc., Merck & Co., Inc., Mylan N.V, Nastech Pharmaceutical Company Inc., Nidda Healthcare, Novartis Ag, Patrick Parsons, Pfizer Inc., Procter And Gamble, Rugby Laboratories and Sandoz International Gmbh among others.
November 2019, Sandoz announced that it has entered into a binding agreement for the planned acquisition of the Japanese business of Aspen Global Incorporated (AGI), a wholly owned subsidiary of Aspen Pharmacare Holdings Limited. Strengthening position in world’s third largest generics market.
June 2019: AptarGroup, Inc. acquired two pharmaceutical services companies, Nanopharm Ltd. and Gateway Analytical LLC. The acquisitions are part of strategy to broaden its portfolio of services which supports pharmaceutical and biotech customers to accelerate their complex product development.
April 2019: Cipla Ltd. acquired 30% Stake in South African's Brandmed For Business Expansion. The Acquisition was carried out to pair the company’s strengths with Brandmed’s innovative, patient-centric approach to healthcare which will enhance Cipla Medpro’s portfolio.
December 2018: Procter & Gamble (P&G) completed the acquisition of Merck’s Consumer Health business. It is intended to improve P&G’s over the counter (OTC) geographic scale brand portfolio and category footprint across 15 markets.
The report analyses the nasal decongestant market based on product type, application and country. The various product type covered in the market are nasal strips, tablets, sprays and capsules. Based on application, the market is segmented into asthma, cold and nasal allergies. The report also analysed the impact of COVID-19 on the nasal decongestant market and it analyses that the healthcare and pharmaceutical companies are going through high pressure for drug innovation to treat coronavirus in patients. The invention of vaccines by key players has lowered the pressure on the pharmaceutical companies to launch drugs for the novel infection. However, key players in nasal decongestant market are rising their R&D efforts. Due to these the nasal decongestant market have experienced positive impact during COVID-19 pandemics. The study also imparts the major key players operating in the market.
Why to buy this report
